INVESTING IN BIOMEDICAL DISCOVERIES

LASCCO SA is a biomedical-technology development private company based at the Biopole of Lausanne, Switzerland.

The primary objective of LASCCO is to bring promising early-stage biomedical technologies – therapeutics and diagnostics – developed in research institutes to the attention of the pharmaceutical industry.

The company’ portfolio is currently composed of two critical care products based on innovative technologies and aiming at fighting sepsis and treating severe bacterial and viral infections.

LATEST NEWS

LASCCO’s spin-off Combioxin SA announces worldwide licensing agreement with Eagle Pharmaceuticals for Phase 2b/3, first-in-class anti-virulence agent CAL02 for the treatment of severe pneumonia.
August 25, 2021

LASCCO’s partner Abionic launches first Covid-19 Severity Test to triage patients quickly and accurately, based on PSP.
November 26, 2020

MEET THE TEAM

Samareh Azeredo da Silveira

Managing Director

Frédéric Lajaunias

Managing Director

Toni Perez

Chief Medical Director